CME: How to Approach Liquid Biopsy in the Treatment of NSCLC

How to Approach Liquid Biopsy in the Treatment of NSCLC

How to Approach Liquid Biopsy in the Treatment of NSCLC

The use of liquid biopsy in the management of non-small cell lung cancer is continuing to grow. Here’s how you can use it to your advantage.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Learn insightful information around the treatment of non-small cell lung cancer (NSCLC) with thoughtful consideration of novel sampling applications, genomic mutations, and resistance mechanisms. 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mark A. Socinski, MD
    Executive Medical Director
    AdventHealth Cancer Institute
    Orlando, FL

    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novartis 
    Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Ming-Sound Tsao, MD, FRCPC
    Consultant Pathologist
    Professor of Laboratory Medicine and Pathobiology
    University Health Network
    University of Toronto
    Toronto, Ontario, Canada

    Consulting Fees: AstraZeneca, Bayer, BMS, Merck, Takeda
    Contracted Research: Bayer

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Feidel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Improve knowledge and confidence of the evolving role of liquid biopsy to support identifying tumor mutations and aid the implementation precision medicine
    • Discuss the advantages and limitations of liquid biopsy (circulating plasma/tumor DNA, circulating tumor cells) vs. tissue sampling in NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pathologists, and other healthcare professionals that manage patients with NSCLC.

  • Accreditation and Credit Designation Statements

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Agile. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Agile you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free